FATE-NK100 as Monotherapy and in Combination with Monocl

Project: Research project

Description

FATE-NK100 as Monotherapy and in Combination with Monoclonal Antibody in Subjects with Advanced Solid Tumors
StatusActive
Effective start/end date8/1/178/30/21

Funding

  • Fate Therapeutics, Inc.

Fingerprint

Monoclonal Antibodies
Neoplasms